Under the terms of the collaboration, Twist will leverage its proprietary Library of Libraries to discover five novel antibodies directed against MediSix's targets.
MediSix will use its unique platform technologies to develop novel CAR T-cell therapies targeting malignancies and autoimmune diseases without any CAR T-cell fractricide.
Twist will receive an upfront payment and will be eligible to receive success-based clinical and regulatory milestone payments, as well as royalties on product sales.
An expert in cell therapy and the creator of the first anti-CD19 CAR, Professor Dario Campana founded MediSix Therapeutics in 2016 to help patients with B-cell malignancies.
Since then, MediSix Therapeutics has developed and leveraged on several unique groundbreaking proprietary technologies to build a pipeline of research products with the aim of overcoming the major challenges in the treatment of cancer and autoimmune diseases.
Their investors include Temasek Holdings, Lightstone Ventures, Osage University Partners and National University of Singapore.
Twist Bioscience is synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip.
Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing preparation, and antibody libraries for drug discovery and development.
Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.
Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca